PRIMARY STUDY
Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy
Key Findings: In patients with diabetic nephropathy already taking a renin-angiotensin inhibitor, with elevated low-density lipoprotein cholesterol (LDL-C) levels, and well-controlled blood pressure, levels of liver-type fatty acid-binding protein (L-FABP) decreased significantly after 6 months in the group taking rosuvastatin. This suggests that rosuvastatin may provide additional benefits against oxidative stress, and can reduce inflammatory systatin C levels in this patient population.
Type of Study: Clinical Trial
Study Sample Size: 104
Study Result: Positive
Research Location(s): Japan
Year of Pub: 2011
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Ligands Studied: Insulin, Pro-inflammatory cytokines
Dosage: rosuvastatin (2.5-10 mg per day)
Route of Administration: Endogenous, Oral (Ingestion)
Citation: Abe M, et al. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011; 18:1018-28. doi: 10.5551/jat.9084
Authors: Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M
